Integra LifeSciences/$IART
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Integra LifeSciences
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
- Ticker
- $IART
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,427
- Headquarters
- Princeton, United States
- Website
- www.integralife.com
IART Metrics
BasicAdvanced
$992M
75.92
$0.17
1.21
-
Price and volume
Market cap
$992M
Beta
1.21
52-week high
$20.49
52-week low
$8.70
Average daily volume
1.2M
Financial strength
Current ratio
3.617
Quick ratio
1.705
Long term debt to equity
1.818
Total debt to equity
1.878
Interest coverage (TTM)
1.78%
Profitability
EBITDA (TTM)
316.839
Gross margin (TTM)
56.44%
Net profit margin (TTM)
0.79%
Operating margin (TTM)
9.90%
Effective tax rate (TTM)
41.66%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
2.86%
Return on equity (TTM)
1.24%
Valuation
Price to earnings (TTM)
75.923
Price to revenue (TTM)
0.596
Price to book
0.93
Price to tangible book (TTM)
-1.7
Price to free cash flow (TTM)
22.047
Free cash flow yield (TTM)
4.54%
Free cash flow per share (TTM)
0.578
Growth
Revenue change (TTM)
0.84%
Earnings per share change (TTM)
-102.53%
3-year revenue growth (CAGR)
2.41%
10-year revenue growth (CAGR)
5.34%
3-year earnings per share growth (CAGR)
-48.97%
10-year earnings per share growth (CAGR)
-14.15%
What the Analysts think about IART
Analyst ratings (Buy, Hold, Sell) for Integra LifeSciences stock.
Analyst projections of the future price of Integra LifeSciences stock.
Bulls say / Bears say
Third-quarter adjusted EPS rose to $0.59 from $0.54 a year earlier, while operating cash flow reached $96 million and leverage fell to 3.8 times. This points to stronger cash generation and gradual balance-sheet repair. (Integra LifeSciences)
Integra’s second-quarter adjusted EBITDA margin expanded to 18.7% from 17.1%, and adjusted EPS rose 24% to $0.56. Manufacturing efficiencies and cost-saving measures are helping profitability recover even as sales growth remains modest. (Integra LifeSciences)
Specialty Surgery, which contributes about 70% of revenue, grew 4.2% organically in the third quarter despite a roughly $7 million flood-related impact. Neuro sales rose 6.5%, showing resilience in the company’s largest segment. (Integra LifeSciences)
Flooding at the Cincinnati facility is expected to cut fourth-quarter revenue by $15 million to $20 million, and full production is not expected until the second quarter of 2027. Integra also lowered its 2026 revenue and adjusted EPS outlook after the disruption. (Integra LifeSciences)
FDA quality-system warning letters remain unresolved, and the company says related Class III premarket approvals cannot be granted until the violations are corrected. Continued remediation or further regulatory action could delay product approvals and disrupt sales. (SEC)
Leverage remains elevated at 3.8 times, and the refinancing includes $450 million of notes carrying 9.5% interest. Integra expects refinancing to add about $8 million of interest expense in the fourth quarter and a further $24 million in 2027 versus its updated 2026 outlook. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
IART Financial Performance
Revenues and expenses
IART Earnings Performance
Company profitability
Upcoming events
No upcoming events
IART News
AllArticlesVideos
Lost Money on Integra LifeSciences Holdings Corporation Shares? The Law Offices of Frank R.
Business Wire1 week ago
Integra LifeSciences Holdings Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your IART Investments
Newsfile Corp2 weeks ago
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call
MarketBeat2 weeks ago
Funds containing IART
Fund name | Fund size | $IART weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.08% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.08% |
iShares Ageing Population£AGES | $953M | 0.08% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.08% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.